H.C. Wainwright & Co. Initiates Coverage on atai Life Sciences, With Buy Rating And US$40 Price Target

October 18, 2021

H.C. Wainwright is initiating coverage of atai Life Sciences with a Buy rating and $40/share price target. atai is aiming to bring meaningful change to mental health challenges through psychedelic derived medicines and digital therapeutics.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.